Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1958 2
1959 1
1962 1
1963 1
1964 1
1965 5
1966 2
1968 5
1969 9
1970 15
1971 12
1972 18
1973 12
1974 23
1975 23
1976 20
1977 24
1978 32
1979 23
1980 27
1981 33
1982 36
1983 33
1984 42
1985 44
1986 50
1987 68
1988 56
1989 69
1990 74
1991 74
1992 81
1993 92
1994 63
1995 95
1996 95
1997 102
1998 95
1999 93
2000 70
2001 87
2002 76
2003 91
2004 99
2005 88
2006 98
2007 113
2008 105
2009 96
2010 151
2011 128
2012 143
2013 150
2014 175
2015 154
2016 195
2017 202
2018 164
2019 198
2020 199
2021 200
2022 188
2023 184
2024 151
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

321 results

Results by year

Filters applied: . Clear all
Page 1
Lactulose.
Mukherjee S, Patel P, John S. Mukherjee S, et al. 2024 Feb 28. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. 2024 Feb 28. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. PMID: 30725615 Free Books & Documents.
Lactulose is a versatile pharmaceutical agent helpful in preventing and treating clinical portal-systemic encephalopathy. ...Beyond its established efficacy in portal-systemic encephalopathy, lactulose has garnered recognition as a potential therapeutic solution for …
Lactulose is a versatile pharmaceutical agent helpful in preventing and treating clinical portal-systemic encephalopathy. ...Beyond i …
Rifaximin plus lactulose versus lactulose alone for reducing the risk of HE recurrence.
Sanyal AJ, Kowdley KV, Reau NS, Pyrsopoulos NT, Allen C, Heimanson Z, Bajaj JS. Sanyal AJ, et al. Hepatol Commun. 2024 May 10;8(6):e0436. doi: 10.1097/HC9.0000000000000436. eCollection 2024 Jun 1. Hepatol Commun. 2024. PMID: 38727685 Free PMC article. Clinical Trial.
METHODS: Pooled post hoc subgroup analysis of adults receiving rifaximin 550 mg twice daily plus lactulose or lactulose alone for 6 months in a phase 3 randomized, double-blind trial and a phase 4 open-label trial was conducted. RESULTS AND CONCLUSION: Rifaximin plu …
METHODS: Pooled post hoc subgroup analysis of adults receiving rifaximin 550 mg twice daily plus lactulose or lactulose alone …
Bifidobacteria metabolize lactulose to optimize gut metabolites and prevent systemic infection in patients with liver disease.
Odenwald MA, Lin H, Lehmann C, Dylla NP, Cole CG, Mostad JD, Pappas TE, Ramaswamy R, Moran A, Hutchison AL, Stutz MR, Dela Cruz M, Adler E, Boissiere J, Khalid M, Cantoral J, Haro F, Oliveira RA, Waligurski E, Cotter TG, Light SH, Beavis KG, Sundararajan A, Sidebottom AM, Reddy KG, Paul S, Pillai A, Te HS, Rinella ME, Charlton MR, Pamer EG, Aronsohn AI. Odenwald MA, et al. Nat Microbiol. 2023 Nov;8(11):2033-2049. doi: 10.1038/s41564-023-01493-w. Epub 2023 Oct 16. Nat Microbiol. 2023. PMID: 37845315 Free PMC article.
We find that patients treated with the orally administered but non-absorbable disaccharide lactulose have increased densities of intestinal bifidobacteria and reduced incidence of systemic infections and mortality. ...Our studies suggest that lactulose and bifidobac …
We find that patients treated with the orally administered but non-absorbable disaccharide lactulose have increased densities of inte …
Diagnosis and Management of Cirrhosis and Its Complications: A Review.
Tapper EB, Parikh ND. Tapper EB, et al. JAMA. 2023 May 9;329(18):1589-1602. doi: 10.1001/jama.2023.5997. JAMA. 2023. PMID: 37159031 Free PMC article. Review.
In meta-analyses of randomized trials, lactulose was associated with reduced mortality relative to placebo (8.5% vs 14%) in randomized trials involving 705 patients and reduced risk of recurrent overt hepatic encephalopathy (25.5% vs 46.8%) in randomized trials involving 1 …
In meta-analyses of randomized trials, lactulose was associated with reduced mortality relative to placebo (8.5% vs 14%) in randomize …
Lactulose therapy for patients with cirrhosis, portal hypertension, and poor patient-reported outcomes: The Mi-Kristal trial.
Tapper EB, Ospina E, Salim N, Chen X, Nikirk S. Tapper EB, et al. Hepatology. 2023 Oct 1;78(4):1159-1167. doi: 10.1097/HEP.0000000000000408. Epub 2023 Apr 18. Hepatology. 2023. PMID: 37066820 Free PMC article. Clinical Trial.
HE is a major driver of poor PROs. Many clinicians initiate lactulose therapy to address poor PROs. PRO-triggered therapy, however, has not been studied till date. ...Lactulose users reported more good sleep (92% vs. 52%, p = 0.001) and lower activity impairment (3. …
HE is a major driver of poor PROs. Many clinicians initiate lactulose therapy to address poor PROs. PRO-triggered therapy, however, h …
Small intestinal bacterial overgrowth: current update.
Zafar H, Jimenez B, Schneider A. Zafar H, et al. Curr Opin Gastroenterol. 2023 Nov 1;39(6):522-528. doi: 10.1097/MOG.0000000000000971. Epub 2023 Sep 18. Curr Opin Gastroenterol. 2023. PMID: 37751393 Review.
Small bowel jejunal aspirate of >10 5 CFU/ml has traditionally been considered the gold standard for diagnosis. Glucose and lactulose breath testing have become more common in clinical practice as they are noninvasive, easily accessible, and have lower cost. ...
Small bowel jejunal aspirate of >10 5 CFU/ml has traditionally been considered the gold standard for diagnosis. Glucose and lactulose …
Epidemiology of small intestinal bacterial overgrowth.
Efremova I, Maslennikov R, Poluektova E, Vasilieva E, Zharikov Y, Suslov A, Letyagina Y, Kozlov E, Levshina A, Ivashkin V. Efremova I, et al. World J Gastroenterol. 2023 Jun 14;29(22):3400-3421. doi: 10.3748/wjg.v29.i22.3400. World J Gastroenterol. 2023. PMID: 37389240 Free PMC article. Review.
Coadministration of Lactulose with Probiotics Ameliorates Loperamide-Induced Constipation in Mice.
Park CW, Lee J, Hong YH, Kim YS, Suh HJ, Ahn Y. Park CW, et al. Prev Nutr Food Sci. 2023 Dec 31;28(4):427-435. doi: 10.3746/pnf.2023.28.4.427. Prev Nutr Food Sci. 2023. PMID: 38188082 Free PMC article.
To evaluate the laxative effects of the lactulose-probiotic and lactulose-magnesium hydroxide mixtures, fecal parameters, the gastrointestinal (GI) transit ratio, and fecal short-chain fatty acid (SCFA) content were analyzed. ...Overall, the combination of lactul …
To evaluate the laxative effects of the lactulose-probiotic and lactulose-magnesium hydroxide mixtures, fecal parameters, the …
Lactulose regulates gut microbiota dysbiosis and promotes short-chain fatty acids production in acute pancreatitis patients with intestinal dysfunction.
Wang J, Jiang M, Hu Y, Lei Y, Zhu Y, Xiong H, He C. Wang J, et al. Biomed Pharmacother. 2023 Jul;163:114769. doi: 10.1016/j.biopha.2023.114769. Epub 2023 Apr 26. Biomed Pharmacother. 2023. PMID: 37116350 Free article. Clinical Trial.
RESULTS: The intestinal dysfunction was prominently improved after 7 days of treatment with either lactulose or rhubarb. The serum levels of cytokines and gut permeability index were decreased after treatment, with stronger down-regulated degree in lactulose group t …
RESULTS: The intestinal dysfunction was prominently improved after 7 days of treatment with either lactulose or rhubarb. The serum le …
Prophylactic Lactulose Therapy in Patients with Cirrhosis and Upper Gastrointestinal Bleeding: A Meta-analysis of Randomized Trials.
Roy A, Giri S, Singh A, Vaidya A, Angadi S. Roy A, et al. J Gastrointestin Liver Dis. 2023 Dec 22;32(4):507-512. doi: 10.15403/jgld-4975. J Gastrointestin Liver Dis. 2023. PMID: 38147599 Free article.
BACKGROUND AND AIMS: Lactulose is the first-line drug for both treatment and secondary prophylaxis for overt hepatic encephalopathy (HE). The use of lactulose for the primary prophylaxis of HE in patients with cirrhosis and acute upper gastrointestinal bleeding (AUG …
BACKGROUND AND AIMS: Lactulose is the first-line drug for both treatment and secondary prophylaxis for overt hepatic encephalopathy ( …
321 results

Searches related to "lactulose"